Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00996021 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Cardiac Conduction of GSK1349572
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00996021 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 42 participants.
The verdict
NCT00996021, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This will be a randomized, partial-blind, placebo-controlled, single dose, cross-over trial investigating the effect of GSK1349572 on cardiac repolarization as compared to placebo in healthy adult males and females. Approximately 42 subjects will be enrolled in this study and will be admitted to the clinic for three separate dosing sessions. Subjects will receive single dose administrations of placebo, a supratherapeutic dose of GSK1349572 (250 mg), and moxifloxacin (400 mg) in random sequence. Safety of subjects will be monitored by clinical observation, measures of vital signs, 12-lead ECGs and clinical laboratory measurements.
Interventions
- DRUG Placebo Suspension
- DRUG Moxifloxacin 400 mg
- DRUG GSK1349572 250 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2009-09 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00996021
The ClinicalTrials.gov registry entry for NCT00996021 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Suspension is the first listed.
NCT00996021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00996021 about?
NCT00996021 is a clinical study titled "Study to Assess Cardiac Conduction of GSK1349572". This will be a randomized, partial-blind, placebo-controlled, single dose, cross-over trial investigating the effect of GSK1349572 on cardiac repolarization as compared to placebo in healthy adult males and females. Approximately 42 subjects will be enrolled in this study and will be admitted to the...
What is the current status of trial NCT00996021?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2009-09. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00996021?
The interventions under investigation include: Placebo Suspension (DRUG), Moxifloxacin 400 mg (DRUG), GSK1349572 250 mg (DRUG).
Who is sponsoring clinical trial NCT00996021?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.